DHAP方案治疗复发难治性非霍奇金淋巴瘤的临床疗效观察  

Clinical study of DHAP regimen for patients with relapsed or refractory in the treatment of advanced non-Hodgkin’s lymphoma

作　　者：鲁明骞[1] 黄慧强[2] 徐光川[2] 许新华[1] 文采红[1] 王杰[1] 彭绪申[1] 

机构地区：[1]三峡大学第一临床医学院宜昌市中心人民医院肿瘤科,湖北宜昌443003 [2]中山大学肿瘤防治中心内科,广东广州510060

出　　处：《中华肿瘤防治杂志》2006年第8期624-625,共2页Chinese Journal of Cancer Prevention and Treatment

摘　　要：为了观察DHAP方案治疗复发难治性非霍奇金淋巴瘤(non Hodgkin’slymphoma,NHL)的临床疗效和不良反应,选择复发难治性NHL患者34例,采用DHAP方案化疗:DDP100mg/m2,静脉滴入3h,d1;Ara C2g/m2,静脉滴入3h,d2,每12h1次;DXM40mg/d,口服或静脉推注,d1～d4。21～28d为1周期,共完成1～6个周期,中位周期数为3.5。34例患者CR11例(32.4%),PR6例(17.6%),SD13例(38.2%),PD4例(11.8%),总有效率为50%(17/34)。主要毒副反应为血细胞下降和消化道反应,其白细胞Ⅲ～Ⅳ度下降发生率为52.9%(18/34),血小板Ⅲ～Ⅳ度下降发生率为73.5%(25/34),Ⅰ～Ⅱ度消化道反应为14.7%(5/34),其他不良反应少见。初步研究结果显示,DHAP方案是治疗复发难治性NHL的有效解救化疗方案,缓解率高,不良反应可以耐受,值得临床进一步观察。This study was to observe the efficacy and toxicity of DHAP regimen for the patient with relapse or refractory advanced non-Hodgkin＇s Lymphoma. Thirty-four patients were treated by DHAP regimen.. Cisplatin 100 mg/m^2 , infused over 3 h every on day 1, arabinoside cytarabine 2 g/m^2 , infused over 3 h, every 12 h for 2 doses, day 2, predisone 40 mg PO/Ⅳ on days 1 to 4. All patients received 1 to 6 cycles of chemotherapy, median cycle was 3.5. All the patients were treated by DHAP regimen. The response rate for the whole group was 50% （17/34）, including 11 complete responses （CR） （32.4%） and 6 partial responses （PR） （17.6%）. Main toxicities were myelosuppression and gastrointestinal symptoms. The incidences of grade Ⅲ -- Ⅳ neutropenia and thrombocytopenia respectively were 52.9 % （18/34） and 73.5 % （25/34）. The grade Ⅰ -- Ⅱ nausea/vomiting was 14. 7 % （5/34）. Other toxicities were mild. DHAP regimen is effective for the patients with relapsed or refractory advanced non-Hodgkin＇s Lymphoma. The response rate is high and toxicity mild. DHAP regimen is warranted with clinical study.

关 键 词：淋巴瘤 非霍奇金/药物疗法 抗肿瘤联合化疗方案/治疗应用 

分 类 号：R733.1[医药卫生—肿瘤]